Natco Pharma Ltd.'s net profit slipped 37% in the third quarter of financial year 2024-2025, thereby missing analysts' estimates.
The pharma firm posted a consolidated net profit of Rs 133 crore in the quarter ended Dec. 31, 2024, as compared to Rs 212.70 crore in the same period last year, according to an exchange filing on Wednesday. This compares to the consensus estimate of Rs 247 crore of analysts tracked by Bloomberg.
The company's revenue dipped to Rs 474.80 crore, representing a 37.4% fall as against Rs 758.60 crore for the year ago period. This compares to the consensus estimate of Rs 877 crore of analysts tracked by Bloomberg.
Its earnings before interest, tax, depreciation and amonatisation tumbled by 86% to Rs 38.79 crore for the October- December quarter from Rs 268.10 crore for the same quarter of the corresponding year.
Margin narrowed drastically to 8.2% for the quarter under review as contrast to 35.3% for the same period of the previous fiscal 2025.
Natco Pharma Q3FY25 Highlights (Consolidated, YoY)
Revenue down 37.4% to Rs 474.80 crore versus Rs 758.60 crore. (Bloomberg estimate at Rs 877 crore)
Ebitda down 86% to Rs 38.79 crore versus Rs 268.10 crore. (Bloomberg estimate at Rs 303 crore)
Margin at 8.2% versus 35.3%. (Bloomberg estimate at 34.50%)
Net profit down 37% to Rs 133.00 crore versus Rs 212.70 crore. (Bloomberg estimate at Rs 247 crore)
Natco Pharma declared its third interim dividend of Rs 1.50 per share of Rs 2 each for the financial year 2024-25. The record date for the dividend is set as Feb. 18 and the payment for the same to the eligible shareholders will be done on Feb. 28.
Shares of Natco Pharma closed 1.90% lower at Rs 1,218.80 apiece on the NSE, compared to a 0.12% fall in the benchmark Nifty 50. The stock has risen by 46.23% in the last 12 months.
Out of 12 analysts tracking the company, six maintain a 'buy' rating on the stock, two recommend 'hold,' and four suggest 'sell,' according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 19.7%.
RECOMMENDED FOR YOU
Bajaj Finance, Tata Communications, Delhivery, ACC, MTAR Tech, NATCO Pharma, UPL Are Buzzing On Dealers' Desk
Jul 03, 2025
Natco Pharma's Division In Hyderabad Gets Seven FDA Observations
Jun 19, 2025
.png?rect=0%2C0%2C3500%2C1969&w=75)
NATCO Pharma's Hyderabad API Manufacturing Facility Gets One Observation From USFDA
Jun 13, 2025
Natco Pharma Q4 Results: Profit Misses Estimates, Margin Contracts; FY26 Outlook Gloomy
May 28, 2025
POPULAR